

SUPPLEMENTARY MATERIAL

Supplementary File (PDF)

Figure S1. IgAN with minor histomorphologic alterations on light microscopy. **(A)** Representative glomerulus showing mild mesangial matrix expansion without mesangial hypercellularity on periodic acid–Schiff stain, original magnification $\times 40$. **(B)** Immunofluorescence microscopy with 3+ granular mesangial reactivity for IgA, original magnification $\times 10$. Bar = 20 μm **(A)** and 50 μm **(B)**.

Figure S2. IgAN with cellular glomerular crescents. **(A)** Moderate interstitial fibrosis is evident on the trichrome stain. **(B)** The glomerulus on the left shows a segmental cellular crescent, and the glomerulus on the right shows segmental mesangial hypercellularity with mild mesangial matrix expansion on periodic acid–Schiff stain. **(C)** Immunofluorescence staining shows 2+ granular mesangial staining for IgA. **(D)** Electron microscopy shows electron-dense deposits in mesangium. Bar = 600 μm **(A)**, 60 μm **(B,C)**, and 1 μm **(D)**.

1. Rahim SEG, Lin JT, Wang JC. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination. *Kidney Int.* 2021;100:238.
2. Negrea L, Rovin BH. Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy. *Kidney Int.* 2021;99:1487.
3. Perrin P, Bassand X, Benotmane I, Bouvier N. Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy. *Kidney Int.* 2021;100:466–468.
4. Tan HZ, Tan RY, Choo JCJ, et al. Is COVID-19 vaccination unmasking glomerulonephritis? *Kidney Int.* 2021;100:469–471.

Christian Hanna¹, Loren P. Herrera Hernandez², Lihong Bu³, Sarah Kizilbash⁴, Lydia Najera⁴, Michelle N. Rheault⁴, Jan Czyzyk³ and Anne M. Kouri⁴

¹Division of Pediatric Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA; ²Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA; ³Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA; and ⁴Division of Pediatric Nephrology, University of Minnesota, Minneapolis, Minnesota, USA

Correspondence: Anne M. Kouri, 2450 Riverside Ave, Corporate Bldg, Minneapolis, Minnesota 55454, USA. E-mail: akouri@umn.edu

Kidney International (2021) **100**, 705–706; <https://doi.org/10.1016/j.kint.2021.06.032>

Copyright © 2021, International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Granulomatous vasculitis after the AstraZeneca anti-SARS-CoV-2 vaccine



To the editor: Several reports of newly diagnosed or relapses of immune-mediated renal diseases following vaccination with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA and AstraZeneca vaccines recently emerged in the literature.^{1,2}

We report the case of a 77-year-old man who developed an acute granulomatous nephritis associated with vasculitis after the first dose of the AstraZeneca vaccine. The patient had no




Figure 1 | (a,b) On light microscopy, the renal parenchyma is infiltrated by chronic interstitial inflammatory cells and poorly formed granulomas (stars). Some of these granulomas surrounded small vessels, which rarely showed segmental fibrinoid necrosis (arrows). Glomeruli are normal. **(a)** Jones silver stain, original magnification $\times 20$; **(b)** Masson trichrome stain, original magnification $\times 40$.

significant medical history, and serum creatinine (SCr) was 1.2 mg/dl a month before vaccination with a protein-to-creatinine ratio at 0.07 g/g (N = 0.15) of creatinine. Four weeks after injection, the patient presented with fever, night sweating, and anorexia. He was not taking any medication. Laboratory tests revealed acute kidney injury (SCr, 2.7 mg/dl), normal proteinuria, no hematuria, and a C-reactive protein (CRP) level of 200 mg/L. Nasopharyngeal swab for SARS-CoV-2 was negative by polymerase chain reaction, as were anti-SARS-CoV-2 and anti-neutrophil cytoplasmic antibodies (repeated twice 15 days apart). Fluorine-18-fluorodeoxyglucose positron emission tomography scan showed diffuse hypermetabolism of medium vessels, suggesting vasculitis. The kidney biopsy revealed diffuse interstitial edema with noncaseating nonnecrotizing granulomas around small vessels (Figure 1); one showed fibrinoid necrosis. There were no immune deposits. Serum QuantiFERON for tuberculosis was negative, and there were no radiological or biological findings suggestive of sarcoidosis. The patient was started on methylprednisolone, with normalization of SCr and CRP levels within 4 weeks. Interestingly, the patient eventually mounted a humoral response 8 weeks after vaccination.

The association of vasculitis with *influenza* and *pertussis* vaccines has already been described but without granulomatous pattern.³ Although causality between the renal lesions and the AstraZeneca vaccine cannot be definitively proven, the timing—and the absence of other causes—makes the link between the 2 plausible.⁴

1. Morlidge C, El-Kateb S, Jeevaratnam P, Thompson B. Relapse of minimal change disease following the AstraZeneca COVID-19 vaccine. *Kidney Int.* 2021;100:459.
2. Masset C, Kervella D, Kandel-Aznar C, et al. Relapse of IgG4-related nephritis following mRNA COVID-19 vaccine. *Kidney Int.* 2021;100:465–466.
3. Patel C, Shah HH. Vaccine-associated kidney diseases: a narrative review of the literature. *Saudi J Kidney Dis Transpl.* 2019;30:1002–1009.